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Background: Insulin, insulin-like growth factor-1 (IGF-1), and inflammation possibly
are involved in cats with asymptomatic hypertrophic cardiomyopathy (aHCM).
Objectives: To evaluate echocardiography, morphology, cardiac and inflammatory
markers, insulin and IGF-1 in cats with aHCM.
Animals: Fifty-one client-owned cats with aHCM.
Methods: Observational descriptive study. Variables (body weight [BW], body
condition score [BCS], echocardiography, and serum concentrations of N-terminal
pro-B-type natriuretic peptide [NT-proBNP], ultra-sensitive troponin-I [c-TnI],
serum amyloid A [SAA], insulin, glucose and IGF-1) were evaluated for significant
increases above echocardiography cutoff values and laboratory reference
ranges, associations and effect of left atrial (LA) remodeling and generalized
hypertrophy.
Results: Cats with aHCM had BCS ≥6/9 (P = .01) and insulin (P < .001), NT-proBNP
(P = .001) and cTn-I (P < .001) above laboratory reference ranges. Associations were
present between NT-proBNP and maximum end-diastolic interventricular septum
thickness (IVSd; ρ = .32; P = .05), maximum end-diastolic left ventricular free wall
thickness;(ρ = .41; P = .01), LA/Aorta (ρ = .52; P = .001) and LA diameter (LA-max;
ρ = .32; P = .05); c-TnI and LA/Aorta (ρ = .49; P = .003) and LA-max (ρ = .28; P = .05);
and SAA and number of IVSd regions ≥6 mm thickness (ρ = .28; P = .05). Body weight
and BCS were associated with IGF-1 (r = 0.44; P = .001), and insulin (ρ = .33; P = .02),
glucose (ρ = .29; P = .04) and IGF-1 (ρ = .32; P = .02), respectively. Concentrations of
Abbreviations: aHCM, asymptomatic hypertrophic cardiomyopathy; Ao, aorta; APP, acute phase proteins; BCS, body condition score; BW, body weight; CHF, congestive heart failure; CRP, C-
reactive protein; cTnI, cardiac troponin-I; HCM, hypertrophic cardiomyopathy; IGF-1, insulin-like growth factor − 1; IL-6, interleukin-6; IVRT, isovolumic relaxation time; IVS, interventricular
septum; IVSd, end-diastolic interventricular septum thickness; LA, left atrium / atrial; LV, left ventricle / ventricular; LVFW, left ventricular free wall; LVWd, end-diastolic left ventricular free wall
thickness; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PW-TDI, pulsed wave tissue Doppler imaging; RVFW, right ventricular free wall; RVOT/PA, right ventricular outflow tract/
pulmonary artery; SAA, serum amyloid A; TNF-α, tumor necrosis factor-α.
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NT-proBNP (P = .02) and c-TnI (P = .01), and SAA (P = .02), were higher in cats with
LA remodeling, and generalized hypertrophy, respectively.
Conclusions and clinical importance: Results suggest potential implications of insulin,
IGF-1, and inflammation in cats with aHCM, but it remains to be confirmed whether
these findings represent a physiological process or a part of the pathogenesis and
development of disease.
K E YWORD S
cardiac hypertrophy, cat, hypertrophic obstructive cardiomyopathy, insulin/IGF-1 mediated
growth
1 | INTRODUCTION
In humans, insulin and insulin-like growth factor-1 (IGF-1) are criti-
cally involved in regulation of cardiomyocyte growth, by acting as an
agonist on different signaling pathways including binding of insulin
and IGF-1 to their receptors on the cardiomyocyte, stimulating myo-
cardial protein synthesis and causing ventricular hypertrophy.1-3 A
comparable mechanism possibly involving insulin resistance, the
growth hormone-IGF-1 axis, or both may play a role in hypertrophic
cardiomyopathy (HCM) in cats.1 Some, but not all, studies in cats
with HCM have identified insulin resistance and increased growth
hormone or IGF-1 concentrations.4-7 Maine Coon cats with HCM
are skeletally larger and have higher IGF-1 concentrations than
Maine Coon cats without HCM.5 Moreover, IGF-1 is associated with
hypertrophy of the interventricular septum (IVS) and left ventricular
free wall (LVFW).8 Cats with hypersomatotropism have a greater
maximum LVFW, which decreases significantly after surgical
hypophysectomy.9
Heart failure is associated with high LV filling pressures, hyp-
oxia and tissue ischemia, and stimulating monocyte activation with
subsequent release of cytokines such as tumor necrosis factor
alpha (TNF-α) and interleukin-6 (IL-6).10-12 Indeed, cats with con-
gestive heart failure (CHF) caused by cardiomyopathies including
hypertrophic cardiomyopathy have increased plasma concentrations
of TNF-α.13 Interleukin-6 also can be produced by keratinocytes,
endothelial cells, and fibroblasts.14 Interleukin-6 has been shown to
cause myocyte hypertrophy, inhibition of cardiomyocyte apoptosis,
alteration of protein synthesis,14 and stimulation of hepatocytes to
produce acute phase proteins (APP) such as C-reactive protein
(CRP) and serum amyloid A (SAA), facilitating release of APP into
the blood.12,15 Progression of disease depends on the relative bal-
ance between pathological inflammatory pathways and physiologi-
cal inflammation (ie, tissue reparative processes).16 Humans with
HCM have evidence of systemic inflammation before developing
CHF,17 but in cats it is unclear if, and at what stage, inflammation
plays a role in HCM. Although the assumed role of SAA is
protecting tissues from excessive damage caused by inflammatory
mediators,14 IL-6 driven mechanisms will aggravate the ongoing
process.
We hypothesized that, in cats with aHCM, insulin, IGF-1 and
inflammation possibly are involved in cardiac hypertrophy, and our
objectives were to evaluate these factors in cats with aHCM.
2 | MATERIALS AND METHODS
Ours was an observational descriptive study, evaluating age, BW,
BCS, echocardiography, and serum concentrations of insulin, glucose,
IGF-1, NT-proBNP, cardiac troponin-I (cTnI), and SAA in cats with
aHCM. All owners signed an informed consent form before enrolling
their cats in the study, and ethical approval was obtained from the
Royal Canin Ethics Committee and University of Liverpool's Commit-
tee on Research Ethics (VREC335) and University of Edinburgh Com-
mittee on Research Ethics (VREC 93.16).
Adult cats 8 months of age and older were recruited from 4 differ-
ent centers in the United Kingdom (University of Liverpool [UL],
Anderson Moores Veterinary Specialists [AM], University of Edin-
burgh [UE] and North Downs Specialist Referrals [ND]). To be eligible,
cats had to be diagnosed with HCMby echocardiography and be with-
out clinical signs of heart disease (International Small Animal Cardiac
Health Council stage 1b).18 Cats were excluded if they had important
concurrent systemic disease based on history, physical examination,
blood pressure, and laboratory testing (serum biochemistry profile
and serum total thyroxine [T4] concentration). Cardiac medication
was allowed but it had to have been administered for at least 8 weeks
before inclusion. If cardiac medication was deemed clinically neces-
sary after diagnosis of HCM, all examinations and analyses were post-
poned for a minimum of 8 weeks.
Physical examinations, BCS, blood pressure measurement, and echo-
cardiographywere performed by a board-certified cardiologist. Body con-
dition score was assessed on a 9-point scale.19 Blood pressure was
measured by Doppler technique using the mean of 3 systolic measure-
ments, after recording at least 5 serial measurements, after acclimatiza-
tion of the cat, and selecting 3 measurements that were within 10% of
each other, to obtain the mean. Cats with systolic blood pressure
>180 mmHgwere considered hypertensive and excluded from the study.
All cats had a full echocardiographic assessment, including left
ventricular diastolic function and estimation of filling pressures.
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Echocardiography was performed on conscious cats without chemical
restraint. Right parasternal 4- and 5-chamber long-axis views and short-
axis views at different levels (papillary muscle, mitral valve, and aortic
valve) were obtained. Two-dimensional (2D) measurements of the inter-
ventricular septum, the left ventricular cavity and left ventricular free
wall at end of diastole and systole were made on the short-axis view at
papillary muscle level, using blood-endocardial interface and myocardial-
epicardial interface to guide caliper placement. The 2D interventricular
septum and left ventricular free wall measurements were obtained from
the right parasternal short- and long-axis (4- or 5-chamber) view of the
left ventricle at end-diastole.4 The IVSd was measured in basal, mid, and
apical regions, and LVWd was measured in basal and mid regions from
right parasternal long axis 4- or 5-chamber views, whichever optimized
any focal hypertrophy. The measurements were noted as maximum
thickness measured (max-) and the number of regions with ≥6 mm thick-
ness (n-).20 Generalized hypertrophy was defined as thickness ≥6 mm in
all regions of both IVSd and LVWd. The maximal left atrial (LA) diameter
(LA-max) was obtained from a right parasternal long axis 4-chamber
view, which optimized the LA. Diameter was measured between the
interatrial septum and LA free wall, bisecting the LA, at end of systole.
The 2D LA and aortic dimensions were obtained from the right par-
asternal short-axis view, optimizing LA size, at the end of diastole (start
of QRS complex), when endocardial borders could be reliably visualized.
Left atrial enlargement was defined as LAmax ≥16 mm,21 short axis end-
diastolic ratio LA/Aorta (LA/Ao) ≥ 1.5 or both.22 Hypertrophic cardiomy-
opathy was diagnosedwhen the thickest IVSd or LVWd segment or both
on 2D-mode measured ≥6 mm,23 after exclusion of cardiac or systemic
conditions that could result in hypertrophy.
Cats were fasted overnight before blood sampling. Blood was
collected by cephalic or jugular venipuncture into serum tubes. Samples
were divided into 3 aliquots and frozen at −20C and shipped the
following or same day to Idexx Bioanalytics, Germany. One aliquot was
thawed on the day of arrival for biochemistry analysis (Beckman Coul-
ter AU58000, Beckman Coulter, Brea CA), serum total T4 concentra-
tion (DRI Thyroxine, Microgenics, Fremont, California), c-TnI (ADVIA
Centaur TnI-Ultra Assay, Siemens Healthineers, Germany), glucose
(Immulite 2000/XPi, Siemens Healthineers, Germany), IGF-1 (CLIA, Sie-
mens, Immulite 2000, Idexx, Germany) and SAA (LAA, Eiken Chemical,
Beckman Coulter AU5800, Idexx, Germany). A second aliquot was
stored frozen at −80C, followed by shipment on dry ice to the United
Kingdom for analysis of insulin (IRMA, Beckman Coulter, Nationwide,
UK). The remaining aliquot was thawed on the day of arrival or frozen
at −80C and thawed within 2 days for analysis of NTproBNP (Feline
Cardiopet NT- proBNP Immunoassay, Idexx, Germany).
All continuous variables are described by their median and range (min-
imum-maximum). To test if therewas a significant increase beyond the ref-
erence range of echocardiographic, BCS, and blood measurements, a
1 sample 1-sided t test and a Wilcoxon 1-sided signed ranked test were
used, for normally and non-normally distributed data, respectively.
Because in our investigation the study group was from a different popula-
tion than the population that generated the reference ranges, tests for
independent groups were applied when performing statistical analysis. To
test for significant differences (increase or decrease) in BCS, echocardio-
graphic and blood variables between groups positive or negative for
LAremodeling, general hypertrophy or receiving cardiac medication, a
2-sample 1-sided t test was used when both samples were normally
TABLE 1 Descriptive results for the age, BW, BCS, echocardiography and blood parameters, and significant increases above reference range
where applicable
Variable Median Range Upper reference range




Age (years) 4.42 0.92-17 NA NA NA
BW (kg) 4.7 2.8-8.7 NA NA NA
BCS 5 3-9 ≤5 23 .013a
Max-IVSd (mm) 7 5.4-9.2 ≤5.9 48 <.001a
Max-LVWd (mm) 6.3 4.1-9.1 ≤5.9 33 .005a
LA-max (mm) 16.4 11.4-23.4 ≤15.9 27 .576
LA/Ao 1.29 0.97-2.33 ≤1.49 12 1
Insulin (uU/mL) 22 3.9-113 ≤11.4 42 <.001a
Glucose (mmol/L) 5.9 3.8–11.2 ≤7.8 11 1
IGF-1 (ng/mL) 405 81.2-786 ≤665 7 1
NTproBNP (pmol/L) 179 26-1489 <100 26 <.001a
cTnI (ng/mL) 0.17 0.01-16.45 <0.06 35 <.001a
SAA (mg/L) 0 0-21.8 <3.9 1 1
Abbreviations: BCS, body condition score; BW, body weight; cTnI, cardiac troponin-I; IGF-1, insulin-like growth factor-1; LA/Ao; LA-max, maximum
diameter of left atrium; left atrium to aorta ratio; Max-IVSd, maximum thickness of interventricular septum in diastole; Max-LVWd, maximum thickness of
left ventricular free wall in diastole; SAA, serum amyloid A.
aP value <.05.
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distributed or a Wilcoxon 1-sided ranked test was used otherwise. To
explore for possible associations between 2 different measurements, the
Pearson correlation for normally (and also homogeneously) distributed
continuous variables, and Spearman correlation for non-normally distrib-
uted continuous variables or continuous-ordinal variables, were used. To
investigate if a relationship existed between 2 categorical variables, a Chi-
square test was performed because the data were unpaired. Because
thereweremany comparisonswithin the same hypothesis (eg, in the block
of LA remodeling, there were 17 comparisons), it was decided to keep the
test procedure exploratory so as not tomiss any results of interest. Conse-
quently, a significance level of .05 was applied for all tests. All statistical
analyseswere performed using SAS software version 9.4 (2014).
3 | RESULTS
3.1 | Study population
Fifty-one cats were recruited from the 4 centers between November
2015 and June 2017. Numbers of cats from the centers differed, with
25 cats from UL, 19 cats from AM, 4 cats from UE, and 3 cats from
ND. Seventeen cats were female and 34 cats were male. There were
36 domestic short- and long-hairs, 4 British shorthairs, and 11 cats of
other breeds (3 Selkirk Rex, 1 Maine Coon, 1 Exotic Shorthair, 1 Per-
sian, 1 Persian cross, 1 Bengal, 1 Siamese, 2 Ragdoll cross). Forty-eight
cats had a murmur on cardiac auscultation. Nine cats had been receiv-
ing cardiac medication for a minimum of 8 weeks at the time of evalu-
ation (atenolol [n = 6], or a combination of atenolol and clopidogrel
[n = 2] or telmisartan [n = 1]).
3.2 | Descriptive results
Table 1 shows the descriptive results for age, BW, BCS, echocardiog-
raphy, and blood variables, and significant increases above echocar-
diographic cutoff values and laboratory reference range where
applicable. Median systolic blood pressure was 131 mmHg (range,
120-142 mmHg).
TABLE 2 Number of cats with hypertrophic regions in IVSd
and LVWd
Number of regions ≥6 mm
LVWd
0 1 2
IVSd 0 NA 0 3
1 7 5 3
2 4 4 4
3 7 3 11
Abbreviations: IVSd, interventricular septum in diastole; LVWd, left
ventricular free wall in diastole.
TABLE 3 Descriptive results of cats with LA remodeling, generalized hypertrophy, and receiving cardiac medication
LA remodeling (n = 27) Generalized hypertrophy (n = 11) Receiving cardiac medication (n = 9)
Variable Median Range
Increaseda compared









to cats not receiving
cardiac medication
(P-value)
Age (years) 4.65 0.92-12.8 .594 6.1 0.92-13.92 .143 7.5 1.7-13.7 .229
BW (kg) 4.7 2.8-6.8 .242 5.6 2.8–8.7 .077 4.7 3.5-6.8 .544
BCS 6 4–7 .054 6 4–9 .239 6 4–7 .500
Max-IVSd (mm) 7 5.5-9.2 .146 8.0 6.0-9.2 .003* 7.6 6-9.2 .066
Max-LVWd (mm) 6.7 4.9-9.1 .016b 7.3 6-9.1 <.001b 6.6 5.1-8.0 .409
LA-max (mm) 17.1 11.4-23.4 <.001b 16.8 12.6-20 .067 16.7 13.0-23.4 .086
LA/Ao 1.34 0.97–2.33 .014b 1.28 1.0-2.0 .673 1.3 1.2-2.3 .030b
Insulin (uU/mL) 21.5 6.3-76 .630 16.7 6-53 .859 23 8.9-33 .530
Glucose (mmol/L) 5.9 3.8-9.5 .519 5.9 4.2-9.5 .709 6.1 5.1-9.5 .264
IGF-1 (ng/mL) 461 81.2-786 .132 482 81.2-730 .432 405 328-786 .412
NTproBNP
(pmol/L)
350 27-1489 .016b 290 42-1489 .500 487 97.0-964 .082
cTnI (ng/mL) .32 0.02-16.5 .009a 0.33 0.02-16.5 .087 0.28 0.03-1.74 .078
SAA (mg/L) 0 0–21.8 .103 0.1 0–21.8 .018a 0 0-21.8 .188
Abbreviations: BCS, body condition score; BW, body weight; cTnI, cardiac troponin-I; IGF-1, insulin-like growth factor-1; LA/Ao, left atrium to aorta ratio;
LA-max, maximum diameter of left atrium; Max-IVSd, maximum thickness of interventricular septum in diastole; Max-LVWd, maximum thickness of left
ventricular free wall in diastole; SAA, serum amyloid A.
aDecreased values compared to cats without LA remodeling/general hypertrophy/medication P decrease value = 1 − Pincrease value.
bP value < .05.
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Both NT-proBNP and cTnI had missing data with results above
and below the detection limit, although sensitivity analysis showed
comparable conclusions with and without imputations.
On echocardiography, cats had focal or multifocal hypertrophy
but the largest number of cats had generalized hypertrophy with
hypertrophy in all regions of IVSd and LVWd (Table 2). Of the
51 cats, 28 cats had LA remodeling, 11 cats had generalized hyper-
trophy, and 7 cats had both LA remodeling and generalized
hypertrophy.
Of the 28 cats showing LA remodeling, 17 cats had either LA max
≥16 mm (n = 16) or LA/Ao ≥1.5 (n = 1), and 11 cats had both LA max
≥16 mm and LA/Ao ≥1.5. In cats with LA max ≥16 mm, LA/Ao ≥1.5 or
both, LA max ranged from 11.4 to 23.4 mm, with a median of 17 mm,
and LA/Ao ratio ranged from 0.97 to 2.33 with a median of 1.3. Cats
with LA remodeling had significantly higher MAX-LVWd on echocardi-
ography and significantly higher blood concentrations of NT-proBNP
and cTnI compared to cats without LA remodeling (Table 3).
Cats with generalized hypertrophy had significantly higher SUM-
LVWd and LA-max on echocardiography, and significantly higher
blood concentrations of SAA, compared to cats without general
hypertrophy (Table 3).
Cats receiving cardiac medication for a minimum of 8 weeks only
had significantly higher LA/Ao (Table 3).
3.3 | Associations
Correlation analysis showed significant associations between several
of the evaluated variables. Results are shown grouped according to
echocardiography, cardiac biomarkers, insulin, glucose, IGF-1, and
SAA, as shown in Table 4.
4 | DISCUSSION
We hypothesized that insulin, IGF-1, and inflammation possibly may
be involved in cardiac hypertrophy in cats with aHCM. We evaluated
these variables as well as age, BW, BCS, echocardiography, and car-
diac markers NT-proBNP and cTnI.
The blood concentration of insulin was significantly above labora-
tory reference range in cats with aHCM. Forty-two of the 51 cats
(82%) were hyperinsulinemic with insulin concentrations up to
113 uU/mL (Table 1). Blood glucose concentration ranged from 3.8 to
11.2 mmoL/L, with 30 of the 42 cats with insulin concentration above
laboratory reference range having normal fasting blood glucose con-
centrations. Cats were fasted overnight before blood sampling and
clinically relevant hyperglycemia (as in diabetes) was excluded, but it
is possible that cats experienced mild hyperglycemia associated with
stress. Biological variability and insulin concentrations above the ref-
erence range in clinically healthy cats have been described previously,
but using a different assay for determination of serum insulin concen-
trations.24 Previous studies have shown that insulin concentrations
were comparable in healthy cats with and without LVH,8 and between
Maine Coon cats with and without HCM.5 This might be a specific
finding in the Maine Coon breed and in our study 1 Maine Coon cat
did not have a blood insulin concentration above reference range.
High insulin concentrations are associated with LVH in clinical studies
of humans.25,26 Through Akt signaling pathways stimulating protein
synthesis and inhibiting protein breakdown in cardiomyocytes, insulin
plays an important role in cardiac hypertrophy in humans.2 Diabetic
cardiomyopathy has been described in humans, with hyperinsulinemia
proposed as 1 of the pathogenic mechanisms.27,28 Existence of a com-
parable cardiomyopathy related to hyperinsulinemia in cats remains
controversial. Although diastolic dysfunction29 and increased risk of
TABLE 4 Significant associations between variables from different parts of the hypothesized mechanism
Echocardiography
Cardiac biomarkers
Insulin, glucose, IGF-1 SAANT-proBNP c-TnI
Age Glucose (ρ = 0.31, P = .03)
BW n-LVWd
(ρ = 0.29, P = .04)
IGF-1 (r = 0.44, P = .001)
BCS Insulin (ρ = 0.33, P = .02)
Glucose (ρ =0.29, P = .04)
IGF-1 (ρ = 0.32, P = .02)
IVSd Max-IVSd (ρ = 0.32, P = .05) n-IVSd (ρ = 0.28, P = .05)
LVWd Max-LVWd (ρ = 0.41, P = .01)
LA LA/Ao (ρ = 0.52, P = .001)
LAmax (ρ = 0.32, P = .05)
LA remodeling (ρ = 0.38, P = .02)
LA/Ao (ρ = 0.49, P = .001)
LAmax (ρ = 0.28, P = .05)
LA remodeling (ρ = 0.38, P = .01)
Abbreviations: BCS, body condition score; BW, body weight; cTnI, cardiac troponin-I; IGF-1, insulin-like growth factor-1; LA/Ao, left atrium to aorta ratio;
LA-max, maximum diameter of left atrium; Max-IVSd, maximum thickness of interventricular septum in diastole; Max-LVWd, maximum thickness of left
ventricular free wall in diastole; n-IVSd, number of regions in interventricular septum in diastole ≥6 mm; n-LVWd, number of regions of left ventricular free
wall in diastole ≥6 mm; SAA, serum amyloid A.
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heart failure30 have been observed in diabetic cats, maximum left ven-
tricular wall thickness was not significantly different in a study com-
paring diabetic and healthy cats.9 The effects of insulin and IGF-1 are
strongly related, because insulin and IGF-1 fully activate their own
receptors, and also, although with decreased affinity, bind and acti-
vate the other receptor.3 In humans, the effect of insulin/IGF-
1-mediated growth is enforced by the increased binding capacity of
the IGF-1 receptor in HCM.31 Insulin and IGF-1 receptor signaling can
contribute to progressive cardiac dysfunction, as has been shown in
fruit flies,32 mice,33 and humans.34,35 In contrast to findings in previ-
ous studies in which IGF-1 was found to be increased in Maine Coon
cats with HCM5 and cats with LVH,8 our study did not show IGF-1 to
be significantly increased above laboratory reference range despite
the fact that some of the cats in our study had high IGF-1 concentra-
tions. The IGF-1 and insulin concentrations were not compared to an
age-matched control group with normal echocardiography coming
from the same referral centers as the cats with aHCM. Moreover, no
association was found between insulin or IGF-1 and echocardio-
graphic parameters and cardiac biomarkers in our study, which leaves
the role of insulin and IGF-1 unclear in these cats with aHCM.
Both BW and BCS were significantly associated with blood con-
centrations of insulin, IGF-1, and glucose in the cats with aHCM in our
study. A possible interaction exists between body size and cardiac
health in cats. Cats with HCM are skeletally larger and heavier at
diagnosis,7,8,36,37 and also are heavier at an early age compared to cats
without HCM.5 A potential mechanism for this interaction may
involve insulin, IGF-1 or both, as described in humans with HCM.
Body morphology or larger stature may simply lead to larger hearts.38
However, in our study, cardiac markers NTproBNP and cTnI were sig-
nificantly increased and associated with the echocardiographic mea-
sures of HCM, as described previously for NTproBNP.39,40 This
finding suggests that the cats in these studies suffered from cardiac
pathology, with cardiomyocyte stretch39 and injury,41 and a thus
physiological variation of heart size was less likely. Another possible
mechanism is cardiomyopathy and increased LV wall thickness associ-
ated with hypersomatotropism.9 This mechanism would be consistent
with the reported manifestations of acromegaly42 and cats with HCM
being skeletally larger.7 Seven cats in our study had serum IGF-1 con-
centrations above the reference range. A positive predictive value of
95% for hypersomatotropism has been established for serum IGF-
1 > 1000 ng/mL.43 The assay in our study uses a more recent stan-
dardization of the kit with an upper reference range at 665 ng/mL.
Whether the positive predictive value of this more recent assay is
comparable remains to be confirmed. These 7 cats had normal fasting
blood glucose concentrations (range, 5.0-7.5 mmol/L), did not show
clinical signs of uncontrolled diabetes such as polydipsia, polyuria, and
polyphagia, nor did they show any of the phenotypical abnormalities
associated with acromegaly.44 Moreover, cardiovascular abnormali-
ties occur late in the course of acromegaly,42 and NTproBNP and cTnI
are not increased in cardiomyopathy associated with acromegaly.9
This makes the presence of such pathogenesis less likely in these cats,
but a final exclusion of acromegaly can be made only with computed
tomography or magnetic resonance imaging.
Cats were subdivided based on the presence or absence of LA
remodeling and generalized hypertrophy. Cats with LA remodeling or
generalized hypertrophy did not have significantly increased blood
concentrations of insulin, IGF-1, or glucose, but cats with LA remo-
deling had significantly increased NTproBNP and cTnI concentrations.
Increased concentration of NTproBNP previously have been reported
to be associated with LA remodeling,39,40,45 and NTproBNP is higher
in severe HCM.46,47 Serum concentration of cTnI also is higher in
severe HCM48 and is described to be higher in cats >10 years of age,
possibly reflecting a subclinical age-related decrease in cardiac func-
tion.49 However, this age is much higher than the median age of the
cats with LA remodeling in our study.
Serum amyloid A concentrations were not significantly increased
above laboratory reference range in the overall population, but were
higher in cats with generalized hypertrophy compared to cats with focal
or multifocal hypertrophy, and were associated with the number of
hypertrophied regions in the interventricular septum. Because no age-
matched healthy control group was included, it is unclear whether this
association is only present in cats in aHCM, or whether it is related to
the pathophysiology of the disease. Serum amyloid A is a major APP in
cats, and is the most rapidly responsive APP to an inflammatory trig-
ger.50 It is unclear whether the higher SAA concentrations in cats with
generalized hypertrophy represent a physiologic (ie, protective) or
pathologic mechanism. The release of IL-6 from activated monocytes
causes myocyte hypertrophy, as well as release of APP, such as SAA in
the blood to protect tissues from excessive damage.14 Median SAA
concentrations in cats with generalized hypertrophy were within labo-
ratory reference range, hence only local inflammation might be present,
with limited monocyte activation. Inflammation has been associated
with CHF in different cardiac diseases and species, including cats with
HCM.13 In addition, histological evidence suggests that cats with
preclinical HCM have mild inflammatory cell infiltrates in the myocar-
dium.51 Local inflammation could explain the higher SAA concentra-
tions in cats with generalized hypertrophy compared to cats with focal
or multifocal hypertrophy and the correlation of SAA with the number
of hypertrophied regions, but it is unclear why SAA concentration is
associatedwith number of hypertrophied regions in the interventricular
septum and not in the left ventricular free wall. Interestingly, SAA has
been described to be higher in cats with diabetes mellitus compared to
healthy cats, but whether any relationship exists with insulin or IGF-1
mediated growth remains unclear.52 Other inflammatory markers such
as serum TNF-α and IL-6 were not evaluated in our study. We did not
perform immunohistochemistry for inflammatory infiltrates in the myo-
cardium, because cats were living and obvious ethical reasons excluded
endomyocardial biopsies, which could have contributed to the identifi-
cation of local inflammation in cardiac tissue.
Nine cats received atenolol either alone or combined with
telmisartan or clopidogrel. Treating asymptomatic cats with HCM
appears rational, but to date there is no proof of a treatment benefit
on morbidity, quality of life, or survival.53 Atenolol treatment previ-
ously has been reported to have no effect on NTproBNP or cTnI,
suggesting that atenolol has no effect on cardiac stretch or car-
diomyocyte injury.54 In our study, cats receiving cardiac medication
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did not have different NTproBNP or cTnI compared to cats not
receiving cardiac medication, which supports this suggestion. Cats
receiving cardiac medication only had significantly increased LA/Ao
compared to cats not receiving cardiac medication. This can be
expected in clinical practice, where cats with more advanced aHCM
are more likely to receive cardiac medications.
Hypertrophic cardiomyopathy in cats is a naturally occurring
model with genotypic and phenotypic similarities to HCM in humans,
although the disease is more severe and progresses more quickly in
cats.55 In humans, circulating concentrations of IGF-1 are related to
the extent of myocardial injury,35 and regional expression of IGF-1 is
increased in the myocardium of patients with HCM.34 It is unclear
whether in cats exogenous modulation of the insulin-IGF-1 axis might
be beneficial in the management of cardiovascular disease with
increased myocardial mass as in humans with HCM.1 Benefits of
omega-3 fatty acids on the production of inflammatory mediators
known to be increased in heart failure remain to be evaluated in
cats.10
Ninety-four percent of cats in our study had murmurs, which is
higher than previously described.36,56 The population in our study
came from referral centers and 1 center actively searched for cats
with cardiac murmurs, which possibly increased the number of cats
with cardiac murmur in our study. Sixteen percent of cats were receiv-
ing cardiac medications, which is lower than previously described.36,56
The evaluation of ventricular wall thickness is done routinely by not-
ing the maximum measured value at any region of the interventricular
septum or LV wall.57 The additional evaluation of noting the number
of areas (3 in the interventricular septum and 2 in the left ventricular
wall) is not a validated method. Nonetheless, this technique was used
to diagnose generalized hypertrophy with a thickness ≥6 mm mea-
sured in all 5 areas, and gives interesting insight into the severity of
cardiac hypertrophy in asymptomatic cats and its association with car-
diac biomarkers, SAA and BW.
A major limitation of our study was the absence of an appropri-
ate control group of age-matched healthy cats without cardiac dis-
ease, preferably from the same geographic location and referral
centers. Because of this limitation, our results can only be regarded
as exploratory. It is unclear whether the described associations also
are present in healthy cats, or whether they represent an important
finding in the pathogenesis of aHCM. Interpretation of the results
was limited to comparing them to widely established cutoff values
for echocardiographic measures23 and laboratory reference ranges
for blood analysis. Laboratory reference ranges are generated from a
healthy cat population and validated by the laboratory performing
the analysis.
Asymptomatic HCM is very common in cats, with a prevalence
approaching 15% in apparently healthy cats.37,58 Interventions that
could alter progression of aHCM into CHF, arterial thromboembolism
or death are still to be defined. Although results from our study sug-
gest potential implications of insulin, IGF-1 and inflammation in the
pathophysiology of aHCM in cats, their precise role as factors in the
development of disease and potential therapeutic targets to slow pro-
gression remains to be confirmed.
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